vs
Side-by-side financial comparison of American Bitcoin Corp. (ABTC) and MESA LABORATORIES INC (MLAB). Click either name above to swap in a different company.
American Bitcoin Corp. is the larger business by last-quarter revenue ($118.0M vs $65.1M, roughly 1.8× MESA LABORATORIES INC). On growth, American Bitcoin Corp. posted the faster year-over-year revenue change (151.5% vs 3.6%). Over the past eight quarters, American Bitcoin Corp.'s revenue compounded faster (296.9% CAGR vs 5.1%).
Bitcoin is the first decentralized cryptocurrency. Based on a free-market ideology, bitcoin was invented in 2008 when an unknown person published a white paper under the pseudonym of Satoshi Nakamoto. Use of bitcoin as a currency began in 2009, with the release of its open-source implementation. From 2021 to 2025, El Salvador adopted it as legal tender currency before revoking it. As bitcoin is pseudonymous, its use by criminals has attracted the attention of regulators, leading to its ban by...
Mesa Laboratories Inc. develops, manufactures and sells professional quality control, calibration and monitoring instruments as well as related supporting services. Its core offerings cater to healthcare, pharmaceutical, food and beverage, industrial hygiene and environmental testing markets, helping global clients meet regulatory compliance and operational safety requirements.
ABTC vs MLAB — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $118.0M | $65.1M |
| Net Profit | — | $3.6M |
| Gross Margin | 49.1% | 64.2% |
| Operating Margin | -192.8% | 12.2% |
| Net Margin | — | 5.6% |
| Revenue YoY | 151.5% | 3.6% |
| Net Profit YoY | — | 316.6% |
| EPS (diluted) | $-0.07 | $0.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $118.0M | $65.1M | ||
| Q3 25 | $64.2M | $60.7M | ||
| Q2 25 | $1.4M | $59.5M | ||
| Q1 25 | $1.6M | $62.1M | ||
| Q4 24 | $46.9M | $62.8M | ||
| Q3 24 | $11.6M | $57.8M | ||
| Q2 24 | $5.5M | $58.2M | ||
| Q1 24 | $7.5M | $58.9M |
| Q4 25 | — | $3.6M | ||
| Q3 25 | $3.5M | $2.5M | ||
| Q2 25 | $3.4M | $4.7M | ||
| Q1 25 | $-100.6M | $-7.1M | ||
| Q4 24 | — | $-1.7M | ||
| Q3 24 | $-576.0K | $3.4M | ||
| Q2 24 | $-61.1M | $3.4M | ||
| Q1 24 | $230.4M | $-254.6M |
| Q4 25 | 49.1% | 64.2% | ||
| Q3 25 | 56.0% | 61.5% | ||
| Q2 25 | — | 62.0% | ||
| Q1 25 | — | 61.8% | ||
| Q4 24 | 57.9% | 63.3% | ||
| Q3 24 | 4.2% | 61.3% | ||
| Q2 24 | 31.0% | 64.0% | ||
| Q1 24 | 35.4% | 62.1% |
| Q4 25 | -192.8% | 12.2% | ||
| Q3 25 | 11.2% | 7.8% | ||
| Q2 25 | -162.1% | 5.1% | ||
| Q1 25 | -350.8% | 2.4% | ||
| Q4 24 | — | 9.2% | ||
| Q3 24 | -87.8% | 6.1% | ||
| Q2 24 | -106.4% | 9.6% | ||
| Q1 24 | -20.8% | -460.6% |
| Q4 25 | — | 5.6% | ||
| Q3 25 | 5.4% | 4.1% | ||
| Q2 25 | 249.2% | 8.0% | ||
| Q1 25 | -6458.5% | -11.4% | ||
| Q4 24 | — | -2.7% | ||
| Q3 24 | -5.0% | 5.9% | ||
| Q2 24 | -1107.2% | 5.8% | ||
| Q1 24 | 3076.2% | -432.2% |
| Q4 25 | $-0.07 | $0.65 | ||
| Q3 25 | $0.06 | $0.45 | ||
| Q2 25 | $-0.07 | $0.85 | ||
| Q1 25 | $-0.09 | $-1.30 | ||
| Q4 24 | $1.10 | $-0.31 | ||
| Q3 24 | $-0.15 | $0.63 | ||
| Q2 24 | $-0.10 | $0.62 | ||
| Q1 24 | $-0.36 | $-47.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $29.0M |
| Total DebtLower is stronger | — | $68.4M |
| Stockholders' EquityBook value | $665.8M | $186.7M |
| Total Assets | $1.2B | $434.8M |
| Debt / EquityLower = less leverage | — | 0.37× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $29.0M | ||
| Q3 25 | — | $20.4M | ||
| Q2 25 | $750.0K | $21.3M | ||
| Q1 25 | $367.0K | $27.3M | ||
| Q4 24 | $850.0K | $27.3M | ||
| Q3 24 | $478.0K | $24.3M | ||
| Q2 24 | $1.4M | $28.5M | ||
| Q1 24 | $1.9M | $28.2M |
| Q4 25 | — | $68.4M | ||
| Q3 25 | — | $69.4M | ||
| Q2 25 | — | $70.3M | ||
| Q1 25 | — | $71.3M | ||
| Q4 24 | — | $72.2M | ||
| Q3 24 | — | $73.1M | ||
| Q2 24 | — | $74.1M | ||
| Q1 24 | — | — |
| Q4 25 | $665.8M | $186.7M | ||
| Q3 25 | $575.5M | $178.5M | ||
| Q2 25 | $339.7M | $172.5M | ||
| Q1 25 | $115.8M | $159.8M | ||
| Q4 24 | $1.0B | $155.2M | ||
| Q3 24 | $697.5M | $161.5M | ||
| Q2 24 | $614.3M | $150.7M | ||
| Q1 24 | $696.8M | $145.4M |
| Q4 25 | $1.2B | $434.8M | ||
| Q3 25 | $1.2B | $430.4M | ||
| Q2 25 | $6.2M | $435.7M | ||
| Q1 25 | $9.0M | $433.3M | ||
| Q4 24 | $1.1B | $433.3M | ||
| Q3 24 | $7.5M | $454.1M | ||
| Q2 24 | $11.4M | $440.4M | ||
| Q1 24 | $17.8M | $446.8M |
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | — | 0.47× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | 0.49× | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-79.6M | $18.8M |
| Free Cash FlowOCF − Capex | — | $18.0M |
| FCF MarginFCF / Revenue | — | 27.7% |
| Capex IntensityCapex / Revenue | — | 1.1% |
| Cash ConversionOCF / Net Profit | — | 5.17× |
| TTM Free Cash FlowTrailing 4 quarters | — | $37.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-79.6M | $18.8M | ||
| Q3 25 | $-39.0M | $8.2M | ||
| Q2 25 | $-879.0K | $1.9M | ||
| Q1 25 | $-3.2M | $12.7M | ||
| Q4 24 | $-54.0M | $18.1M | ||
| Q3 24 | $-76.8M | $5.3M | ||
| Q2 24 | $201.0K | $10.7M | ||
| Q1 24 | $-983.0K | $12.9M |
| Q4 25 | — | $18.0M | ||
| Q3 25 | — | $7.1M | ||
| Q2 25 | $-1.4M | $884.0K | ||
| Q1 25 | — | $11.9M | ||
| Q4 24 | $-60.6M | $17.3M | ||
| Q3 24 | $-79.3M | $3.5M | ||
| Q2 24 | $-874.0K | $9.9M | ||
| Q1 24 | — | $12.3M |
| Q4 25 | — | 27.7% | ||
| Q3 25 | — | 11.7% | ||
| Q2 25 | -104.4% | 1.5% | ||
| Q1 25 | — | 19.2% | ||
| Q4 24 | -129.2% | 27.6% | ||
| Q3 24 | -683.2% | 6.0% | ||
| Q2 24 | -15.8% | 16.9% | ||
| Q1 24 | — | 21.0% |
| Q4 25 | — | 1.1% | ||
| Q3 25 | — | 1.8% | ||
| Q2 25 | 40.5% | 1.7% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | 14.1% | 1.3% | ||
| Q3 24 | 21.6% | 3.1% | ||
| Q2 24 | 19.5% | 1.5% | ||
| Q1 24 | — | 0.9% |
| Q4 25 | — | 5.17× | ||
| Q3 25 | -11.21× | 3.32× | ||
| Q2 25 | -0.26× | 0.40× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.54× | ||
| Q2 24 | — | 3.17× | ||
| Q1 24 | -0.00× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABTC
Segment breakdown not available.
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
